title: Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review.
abstract: OBJECTIVE
  To assess the remission rate of gastric low-grade B-cell mucosa-associated lymphoid tissue lymphoma after an eradication therapy in Helicobacter pylori-negative patients.
  
  
  METHODS
  We performed a systematic review with pooled analysis of published studies. Data were analyzed according to: (1) number of H. pylori-negative patients treated with only eradication therapy; (2) number of patients in whom the complete lymphoma remission was achieved; and (3) the method used to exclude H. pylori infection.
  
  
  RESULTS
  Overall, 11 studies with 110 patients met the inclusion criteria for this pooled analysis. H. pylori infection was excluded in all studies with at least 3 different diagnostic tests. Eradication therapy achieved a complete lymphoma regression in 17 (15.5%; 95% confidence interval, 8.7-22.2) patients.
  
  
  CONCLUSIONS
  Eradication therapy is successful in a small but distinct subgroup of H. pylori-negative patients with low-grade mucosa-associated lymphoid tissue lymphoma. On the basis of the generally indolent behavior of this neoplasia, before resorting to aggressive, costly, and potentially more toxic oncologic therapies, it would seem reasonable to attempt eradication therapy in all patients, irrespective of their H. pylori status.
authors: *Department of Gastroenterology and Digestive Endoscopy, Nuovo Regina Margherita Hospital ‡Oncology Unit, S. Maria Goretti Hospital, Latina, University of Rome "Sapienza", Rome †Gastroenterology Unit, Riuniti Hospital, Foggia §Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, Italy ∥Miraca Research Institute, Miraca Life Sciences, Irving ¶Departments of Pathology and Medicine (Gastroenterology), University of Texas Southwestern Medical Center, Dallas, TX.
authors: Angelo
authors: A
authors: Zullo
authors: Cesare
authors: C
authors: Hassan
authors: Lorenzo
authors: L
authors: Ridola
authors: Vincenzo
authors: V
authors: De Francesco
authors: Luigi
authors: L
authors: Rossi
authors: Silverio
authors: S
authors: Tomao
authors: Dino
authors: D
authors: Vaira
authors: Robert M
authors: RM
authors: Genta
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori / Q000302:isolation & purification; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents